|
Gene: RPL31 |
Gene summary for RPL31 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPL31 | Gene ID | 6160 |
Gene name | ribosomal protein L31 | |
Gene Alias | L31 | |
Cytomap | 2q11.2 | |
Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P62899 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6160 | RPL31 | GSM4909281 | Human | Breast | IDC | 6.32e-16 | -1.88e-01 | 0.21 |
6160 | RPL31 | GSM4909282 | Human | Breast | IDC | 3.04e-29 | -2.94e-01 | -0.0288 |
6160 | RPL31 | GSM4909286 | Human | Breast | IDC | 5.03e-34 | -4.01e-01 | 0.1081 |
6160 | RPL31 | GSM4909287 | Human | Breast | IDC | 5.70e-65 | -8.11e-01 | 0.2057 |
6160 | RPL31 | GSM4909288 | Human | Breast | IDC | 3.14e-14 | -6.62e-01 | 0.0988 |
6160 | RPL31 | GSM4909293 | Human | Breast | IDC | 5.37e-62 | -4.26e-01 | 0.1581 |
6160 | RPL31 | GSM4909294 | Human | Breast | IDC | 2.49e-48 | -7.01e-01 | 0.2022 |
6160 | RPL31 | GSM4909296 | Human | Breast | IDC | 2.84e-22 | 2.68e-01 | 0.1524 |
6160 | RPL31 | GSM4909297 | Human | Breast | IDC | 2.37e-02 | 5.58e-02 | 0.1517 |
6160 | RPL31 | GSM4909299 | Human | Breast | IDC | 1.27e-10 | 2.14e-01 | 0.035 |
6160 | RPL31 | GSM4909303 | Human | Breast | IDC | 1.70e-08 | -4.15e-01 | 0.0438 |
6160 | RPL31 | GSM4909304 | Human | Breast | IDC | 2.31e-77 | -6.07e-01 | 0.1636 |
6160 | RPL31 | GSM4909308 | Human | Breast | IDC | 9.71e-15 | -1.36e-01 | 0.158 |
6160 | RPL31 | GSM4909311 | Human | Breast | IDC | 1.59e-16 | 2.00e-01 | 0.1534 |
6160 | RPL31 | GSM4909312 | Human | Breast | IDC | 6.84e-03 | 1.29e-01 | 0.1552 |
6160 | RPL31 | GSM4909315 | Human | Breast | IDC | 1.61e-33 | -4.69e-01 | 0.21 |
6160 | RPL31 | GSM4909316 | Human | Breast | IDC | 1.12e-23 | -8.41e-01 | 0.21 |
6160 | RPL31 | GSM4909317 | Human | Breast | IDC | 2.71e-77 | -8.49e-01 | 0.1355 |
6160 | RPL31 | GSM4909318 | Human | Breast | IDC | 3.28e-14 | -8.75e-01 | 0.2031 |
6160 | RPL31 | GSM4909319 | Human | Breast | IDC | 8.72e-58 | -1.01e+00 | 0.1563 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0002181113 | Thyroid | PTC | cytoplasmic translation | 121/5968 | 148/18723 | 4.32e-36 | 4.54e-33 | 121 |
GO:0002181210 | Thyroid | goiters | cytoplasmic translation | 73/497 | 148/18723 | 1.65e-75 | 6.83e-72 | 73 |
GO:000218135 | Thyroid | ATC | cytoplasmic translation | 121/6293 | 148/18723 | 1.41e-33 | 1.49e-30 | 121 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL31 | SNV | Missense_Mutation | c.254N>A | p.Arg85His | p.R85H | P62899 | protein_coding | tolerated(0.42) | benign(0.021) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
RPL31 | SNV | Missense_Mutation | c.30N>T | p.Lys10Asn | p.K10N | P62899 | protein_coding | deleterious(0.03) | benign(0.176) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL31 | SNV | Missense_Mutation | c.167A>G | p.Glu56Gly | p.E56G | P62899 | protein_coding | deleterious(0.05) | benign(0.104) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
RPL31 | SNV | Missense_Mutation | c.281N>T | p.Glu94Val | p.E94V | P62899 | protein_coding | deleterious(0.03) | possibly_damaging(0.619) | TCGA-AA-3870-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR | |
RPL31 | SNV | Missense_Mutation | novel | c.329N>A | p.Pro110His | p.P110H | P62899 | protein_coding | deleterious(0.02) | possibly_damaging(0.625) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPL31 | SNV | Missense_Mutation | novel | c.47N>T | p.Ala16Val | p.A16V | P62899 | protein_coding | tolerated(0.06) | benign(0.157) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
RPL31 | SNV | Missense_Mutation | novel | c.74A>G | p.Tyr25Cys | p.Y25C | P62899 | protein_coding | tolerated(0.06) | benign(0.182) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
RPL31 | SNV | Missense_Mutation | rs1065720 | c.284N>G | p.Asp95Gly | p.D95G | P62899 | protein_coding | deleterious(0.01) | benign(0.25) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL31 | SNV | Missense_Mutation | novel | c.31N>G | p.Lys11Glu | p.K11E | P62899 | protein_coding | deleterious(0.05) | benign(0.188) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL31 | SNV | Missense_Mutation | novel | c.154N>G | p.Phe52Val | p.F52V | P62899 | protein_coding | deleterious(0.02) | possibly_damaging(0.566) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |